JENNIFER RUTHERFORD: Open Payments
NPI 1811665078 · LEESBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,493 in 78 payments from 18 companies in 2025. Trend: 2023 $1,604 · 2024 $1,739 · 2025 $1,493
Food & beverage: $1,493
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $349 |
| ABBVIE INC. | 10 | $203 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $183 |
| Novartis Pharmaceuticals Corporation | 8 | $138 |
| Eisai Inc. | 4 | $98 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| Astellas Pharma US Inc | 3 | $54 |
| Exact Sciences Corporation | 3 | $53 |
| GlaxoSmithKline, LLC. | 2 | $50 |
| Abbott Laboratories | 2 | $44 |
Products named: JARDIANCE, CAPLYTA, LEQVIO, VRAYLAR, Leqembi, FARXIGA, Veozah, Cologuard Collection Kit.
Industry payments across FL — which companies pay providers there.
